Sponsor of the Day:
Jerkmate
https://www.statnews.com/2026/02/23/biotech-news-novo-obesity-drug-stumbles-in-lilly-showdown/
Novo Nordisk, Eli Lilly, Gilead, Arcellx: Readout Newsletter
Feb 23, 2026 - Today's biotech news includes Novo's next-gen obesity drug, Gilead buying CAR-T therapy partner Arcellx, and more.
novo nordiskeli lillyreadout newslettergileadarcellx
https://www.arcellx.com/
Arcellx Cell Therapies for Cancer and Autoimmune Diseases
Apr 28, 2026 - At Arcellx, we are pursuing a cure for cancer. With our technology, we're reimagining cell therapy and supercharging how the world treats cancer.
cell therapiesautoimmune diseasesarcellxcancer
https://www.forbes.ro/gilead-preia-arcellx-pentru-78-miliarde-dolari-mizand-pe-terapii-celulare-inovatoare-in-oncologie-489346
Gilead preia Arcellx pentru 7,8 miliarde dolari, mizând pe terapii celulare inovatoare în oncologie...
Feb 25, 2026 - Citeste despre ➜ Gilead preia Arcellx pentru 7,8 miliarde dolari, mizând pe terapii celulare inovatoare în oncologie in Forbes Romania ✅ Afla cele mai noi...
7 8miliarde dolarigileadpreiaarcellx
https://ir.arcellx.com/news/default.aspx
News - Arcellx
newsarcellx
https://www.biospace.com/deals/gilead-doubles-down-on-car-t-with-7-8b-arcellx-acquisition
Gilead Doubles Down on CAR T With $7.8B Arcellx Acquisition - BioSpace
Feb 23, 2026 - The centerpiece of the takeover is anito-cel, a CAR T therapy under development for relapsed or refractory multiple myeloma. An FDA decision on the therapy is...
7 8bgileaddoublescararcellx
https://www.accc.gov.au/public-registers/mergers-and-acquisitions-registers/acquisitions-register/gilead-arcellx
Gilead - Arcellx | ACCC
Gilead Sciences, Inc. (Gilead), through its wholly owned subsidiary Ravens Sub, Inc. (Ravens Sub) proposes to acquire all the outstanding shares of Arcellx,...
gileadarcellxaccc
https://www.arcellx.com/technology/
Our Technology, D-Domains, ARC-SparX Platform, ddCAR Platform - Arcellx
Feb 27, 2025 - Arcellx's technology transforms what cell therapy can do. Read more about our core technology, D-Domains, and related platforms, ARC-SparX and ddCAR.
technologydomainsarcsparxplatform
https://www.genengnews.com/topics/cancer/gilead-to-acquire-arcellx-for-7-8b-adding-anito-cel-to-cancer-pipeline/
Gilead to Acquire Arcellx for $7.8B, Adding Anito-Cel to Cancer Pipeline
Feb 24, 2026 - Gilead Sciences has agreed to acquire Arcellx for $7.8 billion, the companies said today, in a deal intended to give the buyer full control of the buyout...
7 8bgileadacquirearcellxadding